Pancreatic cancer finally has a drug that buys patients more time—and researchers are already racing to figure out why that benefit fades. Daraxonrasib, cleared in August,…
Pancreatic cancer finally has a drug that buys patients more time—and researchers are already racing to figure out why that benefit fades. Daraxonrasib, cleared in August,…
